RARE (STOCKS)
Ultragenyx Pharmaceutical Inc.
$26.380000
-0.480000 (-1.79%)
Prev close: $26.860000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Emil D. Kakkis
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,794.16M
- Employees
- 1,294
- P/E (TTM)
- -4.60
- P/B (TTM)
- -9.07
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $717.21M |
| Benefits Costs and Expenses | $1.30B |
| Costs And Expenses | $1.30B |
| Operating Expenses | $1.25B |
| Selling, General, and Administrative Expenses | $350.56M |
| Research and Development | $773.49M |
| Other Operating Expenses | $121.34M |
| Operating Income/Loss | -$528.17M |
| Income/Loss From Continuing Operations After Tax | -$585.97M |
| Income/Loss From Continuing Operations Before Tax | -$582.23M |
| Income Tax Expense/Benefit | $3.74M |
| Net Income/Loss | -$585.97M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$585.97M |
| Net Income/Loss Available To Common Stockholders, Basic | -$585.97M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$5.83 |
| Diluted Earnings Per Share | -$5.83 |
| Basic Average Shares | 201,484,864 |
| Diluted Average Shares | 201,484,864 |
| Assets | $1.26B |
| Current Assets | $606.00M |
| Inventory | $59.00M |
| Other Current Assets | $547.00M |
| Noncurrent Assets | $658.00M |
| Fixed Assets | $235.00M |
| Intangible Assets | $172.00M |
| Other Non-current Assets | $251.00M |
| Liabilities | $1.55B |
| Current Liabilities | $351.00M |
| Accounts Payable | $39.00M |
| Wages | $63.00M |
| Other Current Liabilities | $249.00M |
| Noncurrent Liabilities | $1.20B |
| Equity | -$291.00M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$291.00M |
| Temporary Equity | $7.00M |
| Liabilities And Equity | $1.26B |
| Net Cash Flow From Operating Activities | -$485.00M |
| Net Cash Flow From Operating Activities, Continuing | -$485.00M |
| Net Cash Flow From Investing Activities | $40.00M |
| Net Cash Flow From Investing Activities, Continuing | $40.00M |
| Net Cash Flow From Financing Activities | $397.00M |
| Net Cash Flow From Financing Activities, Continuing | $397.00M |
| Net Cash Flow | -$48.00M |
| Net Cash Flow, Continuing | -$48.00M |
| Comprehensive Income/Loss | -$585.34M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$585.34M |
| Other Comprehensive Income/Loss | -$91.38M |